$20,000 of ACADIA PHARMACEUTICALS INC. lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Tax Reform - Restoring the Orphan Drug Tax Credit."
You can find more data on corporate lobbying on Quiver Quantitative.
ACAD Insider Trading Activity
ACAD insiders have traded $ACAD stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $ACAD stock by insiders over the last 6 months:
- JAMES KIHARA (PRINCIPAL ACCOUNTING OFFICER) has made 0 purchases and 7 sales selling 21,126 shares for an estimated $506,090.
- MARK C. SCHNEYER (EVP, CHIEF FINANCIAL OFFICER) has made 0 purchases and 5 sales selling 13,600 shares for an estimated $295,671.
- ADAMS CATHERINE OWEN (Chief Executive Officer) sold 11,641 shares for an estimated $249,932
- JENNIFER J RHODES (EVP, CHIEF LEGAL OFFICER, SEC) has made 0 purchases and 2 sales selling 10,794 shares for an estimated $245,021.
- ELIZABETH H.Z. THOMPSON (EVP, Head of Research & Dev) sold 3,435 shares for an estimated $73,749
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
ACAD Hedge Fund Activity
We have seen 138 institutional investors add shares of ACAD stock to their portfolio, and 140 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,474,156 shares (-99.6%) from their portfolio in Q1 2026, for an estimated $55,074,712
- ARTISAN PARTNERS LIMITED PARTNERSHIP added 1,331,813 shares (+inf%) to their portfolio in Q1 2026, for an estimated $29,646,157
- FIRST TRUST ADVISORS LP added 1,073,834 shares (+47.3%) to their portfolio in Q1 2026, for an estimated $23,903,544
- JANE STREET GROUP, LLC added 803,265 shares (+inf%) to their portfolio in Q1 2026, for an estimated $17,880,678
- POINT72 ASSET MANAGEMENT, L.P. removed 799,395 shares (-23.7%) from their portfolio in Q1 2026, for an estimated $17,794,532
- BLACKROCK, INC. added 795,469 shares (+3.8%) to their portfolio in Q1 2026, for an estimated $17,707,139
- EMERALD ADVISERS, LLC removed 782,560 shares (-96.5%) from their portfolio in Q1 2026, for an estimated $17,419,785
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
ACAD Analyst Ratings
Wall Street analysts have issued reports on $ACAD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 02/23/2026
To track analyst ratings and price targets for ACAD, check out Quiver Quantitative's $ACAD forecast page.
ACAD Price Targets
Multiple analysts have issued price targets for $ACAD recently. We have seen 12 analysts offer price targets for $ACAD in the last 6 months, with a median target of $35.0.
Here are some recent targets:
- Brian Abrahams from RBC Capital set a target price of $36.0 on 07/07/2026
- Tazeen Ahmad from B of A Securities set a target price of $30.0 on 06/30/2026
- Yigal Nochomovitz from Citigroup set a target price of $35.0 on 06/29/2026
- Sumant Kulkarni from Canaccord Genuity set a target price of $36.0 on 06/29/2026
- Tessa Romero from JP Morgan set a target price of $34.0 on 03/04/2026
- Jason N. Butler from Citizens set a target price of $35.0 on 02/26/2026
- Ritu Baral from TD Cowen set a target price of $37.0 on 02/26/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
